EraGen Biosciences, Inc. – Trademark Portfolio
Entity Type: 03
EraGen Biosciences, Inc. holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 11 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include MULTICODE. The owner is based in Alachua, FL.
12085 Research Drive
Alachua, FL 32615
Showing of trademarks Trademarks
Trademark Classifications
EraGen Biosciences, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does EraGen Biosciences, Inc. have?
EraGen Biosciences, Inc. has 15 U.S. trademarks filed with the USPTO. Of these, 1 registered, 5 abandoned, 9 cancelled.
What trademark classes does EraGen Biosciences, Inc. file in?
EraGen Biosciences, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are EraGen Biosciences, Inc.'s most well-known trademarks?
EraGen Biosciences, Inc.'s registered trademark portfolio includes well-known marks such as MULTICODE. These are among 1 currently registered trademark in the portfolio.
What is EraGen Biosciences, Inc.'s trademark registration success rate?
EraGen Biosciences, Inc. has a 7% trademark registration rate, with 1 out of 15 resolved applications resulting in successful registration. Currently, 0 applications are pending review.